Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer

Core Insights - Iovance Biotherapeutics has promoted Raj Puri, M.D., Ph.D. to the newly created role of Chief Regulatory Officer, highlighting his significant contributions to the company's regulatory strategy and product pipeline [1][2] Company Overview - Iovance Biotherapeutics focuses on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, aiming to be a global leader in this field [4] - The company’s product, Amtagvi™, is the first FDA-approved T cell therapy for a solid tumor indication, with plans to address over 20,000 patients annually with advanced melanoma starting in 2025 [2][4] Leadership and Experience - Dr. Raj Puri has over 33 years of experience at the FDA, where he held various positions, including director of the Division of Cellular and Gene Therapies, and has been instrumental in the regulatory approval processes for Iovance's products [2][3] - His expertise includes advanced therapies such as cell and gene therapy, cancer vaccines, and cellular immunotherapy, which are critical for Iovance's ongoing product development [2][3] Product Pipeline and Future Prospects - Iovance is advancing its product pipeline, including lifileucel for non-small-cell lung cancer and endometrial cancer, with multiple regulatory milestones expected in 2025 [2] - The company is committed to continuous innovation in cell therapy, including gene-edited cell therapy, to improve patient outcomes [4]